Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Christoph Zielinski, István Láng, Moshe Inbar, Zsuzsanna Kahán, Richard Greil, Semir Beslija, Salomon M. Stemmer, Zanete Zvirbule, Günther G. Steger, Bohuslav Melichar, Tadeusz Pienkowski, Daniela Sirbu, Luboš Petruzelka, Alexandru Eniu, Bella Nisenbaum, Magdalena Dank, Rodica Anghel, Diethelm Messinger, Thomas Brodowicz

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences